1. P102 Sweat chloride is not a useful marker of clinical response to Ivacaftor. (14th November 2013) Authors: Barry, PJ; Flight, WG; Biesty, J; Clough, D; Small, I; Johnson, S; Brennan, AL; Bright-Thomas, RJ; Webb, AK; Jones, AM; Horsley, AR Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P195 Prospective Examination Of The Effects Of Ivacaftor On Glycaemic Health. (10th November 2014) Authors: Banerjee, A; Brennan, AL; Horsley, AR; Barry, PJ Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P247 Lumacaftor/ivacaftor is associated with high discontinuation rates in patients with baseline severe lung function but also benefits in those who tolerate therapy. (15th November 2017) Authors: Wareham, JM; Webb, KA; Jones, AM; Brennan, AL; Bright-Thomas, RJ; Horsley, AR; Barry, PJ Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P255 Reproducibility of lung clearance index (LCI) in clinically stable adults with mild cystic fibrosis (CF). (15th November 2016) Authors: Horsley, AR; Shawcross, A; Oladapo, M; Maitra, A; Cunningham, S; Jones, AM; Smith, J; Gilchrist, F Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S41 Impact of alveolar nitrogen excretion on washout accuracy and progression in a model of multiple breath nitrogen washout. (14th November 2013) Authors: Horsley, AR; Nielsen, J; Nielsen, N Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗